Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Exelixis |
---|---|
Information provided by: | Exelixis |
ClinicalTrials.gov Identifier: | NCT00304590 |
This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with relapsed or refractory multiple myeloma. XL999 is a small molecule inhibitor of cellular factors including VEGFR, PDGFR, and FGFR that may be involved in multiple myeloma.
Condition | Intervention | Phase |
---|---|---|
Multiple Myeloma |
Drug: XL999 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase 2 Study of XL999 in Subjects With Relapsed/Refractory Multiple Myeloma |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Los Angeles, California, United States, 90095 | |
United States, Florida | |
Jacksonville, Florida, United States, 32207 | |
United States, Illinois | |
Chicago, Illinois, United States, 60637 | |
Joliet, Illinois, United States, 60435 | |
United States, Indiana | |
Indianapolis, Indiana, United States, 46202 | |
United States, New York | |
New York, New York, United States | |
United States, Texas | |
Fort Worth, Texas, United States, 76104 |
Study ID Numbers: | XL999-203 |
Study First Received: | March 16, 2006 |
Last Updated: | June 26, 2007 |
ClinicalTrials.gov Identifier: | NCT00304590 |
Health Authority: | United States: Food and Drug Administration |
Immunoproliferative Disorders Hemorrhagic Disorders Multiple myeloma Hematologic Diseases Blood Protein Disorders Blood Coagulation Disorders |
Vascular Diseases Paraproteinemias Lymphoproliferative Disorders Hemostatic Disorders Neoplasms, Plasma Cell Multiple Myeloma |
Neoplasms Neoplasms by Histologic Type Immune System Diseases Cardiovascular Diseases |